Trial · NCT03188666
Results by group84
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 84
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Period 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs | Placebo | Participants with at least one TEAE | 24 | Participants | |
| Period 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs | REGN2477 10 mg/kg Q4W | Participants with at least one TEAE | 20 | Participants | |
| Period 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs | Placebo | Participants with at least one serious TEAE | 2 | Participants | |
| Period 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs | REGN2477 10 mg/kg Q4W | Participants with at least one serious TEAE | 4 | Participants | |
| Period 1: Number of Participants With TEAEs by Severity | Placebo | Participants with at least one Mild TEAE | 9 | Participants | |
| Period 1: Number of Participants With TEAEs by Severity | REGN2477 10 mg/kg Q4W | Participants with at least one Mild TEAE | 7 | Participants | |
| Period 1: Number of Participants With TEAEs by Severity | Placebo | Participants with at least one Moderate TEAE | 12 | Participants | |
| Period 1: Number of Participants With TEAEs by Severity | REGN2477 10 mg/kg Q4W | Participants with at least one Moderate TEAE | 10 | Participants | |
| Period 1: Number of Participants With TEAEs by Severity | Placebo | Participants with at least one Severe TEAE | 3 | Participants | |
| Period 1: Number of Participants With TEAEs by Severity | REGN2477 10 mg/kg Q4W | Participants with at least one Severe TEAE | 3 | Participants | |
Period 1: Time-Weighted Average (Standardized Area Under the Curve [AUC]) of the Percent Change From Baseline in Total Lesion Activity by Fluorine-18-labeled Sodium Fluoride (18^F-NaF) Positron Emission Tomography (PET) at Week 28 (AHO) | Placebo | 16.6 | Standard Error 9.11 | Percent Change | |
Period 1: Time-Weighted Average (Standardized Area Under the Curve [AUC]) of the Percent Change From Baseline in Total Lesion Activity by Fluorine-18-labeled Sodium Fluoride (18^F-NaF) Positron Emission Tomography (PET) at Week 28 (AHO) | REGN2477 10 mg/kg Q4W | -8.1 | Standard Error 9.93 | Percent Change | |
| Period 1: Percent Change From Baseline in the Total Volume of HO Lesions as Assessed by Computed Tomography (CT) at Week 28 (AHO) | Placebo | 32.0 | Standard Error 18.66 | Percent Change | |
| Period 1: Percent Change From Baseline in the Total Volume of HO Lesions as Assessed by Computed Tomography (CT) at Week 28 (AHO) | REGN2477 10 mg/kg Q4W | 7.1 | Standard Error 20.43 | Percent Change | |
| Period 2: Number of New HO Lesions as Assessed by CT at Week 56 Relative to Week 28 Scan (AHO COVID-19 mITT) | Placebo/REGN2477 10 mg/kg Q4W | 0 | New HO Lesions | ||
| Period 1: Time-weighted Average (Standardized AUC) of the Percent Change From Baseline in Total Lesion Activity Assessed by 18^F-NaF PET at Week 28 (AHOC) | Placebo | 17.6 | Standard Error 9.73 | Percent Change | |
| Period 1: Time-weighted Average (Standardized AUC) of the Percent Change From Baseline in Total Lesion Activity Assessed by 18^F-NaF PET at Week 28 (AHOC) | REGN2477 10 mg/kg Q4W | -8.0 | Standard Error 10.14 | Percent Change | |
| Period 1: Percent Change From Baseline in the Total Volume of HO Lesions as Assessed by CT at Week 28 (AHOC) | Placebo | 34.9 | Standard Error 19.90 | Percent Change | |
| Period 1: Percent Change From Baseline in the Total Volume of HO Lesions as Assessed by CT at Week 28 (AHOC) | REGN2477 10 mg/kg Q4W | 7.0 | Standard Error 20.87 | Percent Change | |
Period 1: Time-weighted Average (Standardized AUC) of the Change From Baseline in Daily Pain Due to Fibrodysplasia Ossificans Progressiva (FOP) Assessed by Daily Numeric Rating Scale (NRS) at Week 28 (AHO) | Placebo | -0.17 | Standard Error 0.205 | Score on a Scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03188666/results